Conditions · Glioblastoma
Glioblastoma frontier treatment options
Glioblastoma trials split sharply by newly-diagnosed versus recurrent disease and by MGMT/IDH status. Expanded-access routes exist for several device and agent programs.
Prefer to look first? Browse the live map without signing up.
Open options now (548 open studies; showing 30)
- TRIALNARECRUITING
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
Silibinin as STAT3 inhibitor · Placebo — 16 sites
- TRIALNANOT_YET_RECRUITING
Exploration and Characterization Ofintratumoral Electrophysiological Heterogeneity in Gliomas Using Magnetoencephalography
MEG — 1 site
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
A Study of NST-628 in Recurrent Grade 4 Glioma
NST-628 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Intra-arterial Cetuximab · Intra-arterial Mannitol — 1 site
- TRIALEARLY_PHASE1RECRUITING
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Panitumumab-IRDye800 — 1 site
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Pembrolizumab · Stereotactic Radiation Therapy · Surgical Resection — 1 site
- EXPANDED ACCESSAVAILABLE
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
DNG64-CAR-V — 1 site
- TRIALNARECRUITING
Serial MRI Scans During Radiation Therapy
MRI IMAGING — 2 sites
- TRIALPHASE3RECRUITING
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
Biospecimen Collection · Chemical Exchange Saturation Transfer Magnetic Resonance Imaging · Diffusion-Relaxation Correlation Spectrum Imaging — 1 site
- TRIALNANOT_YET_RECRUITING
Prognostic IntraOperative Biomarkers ideNtification in Tumor rElatEd suRgery
Neuropixel probe recording
- TRIALPHASE1RECRUITING
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
NK cells — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
IA Carboplatin + Radiotherapy in Relapsing GBM
IA Carbo+ Radiation — 1 site
- TRIALEARLY_PHASE1RECRUITING
Window of Opportunity Study of DSP-0390 in Gliomas
DSP-0390 — 1 site
- TRIALPHASE2RECRUITING
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Simultaneous-integrated boost with IMRT — 2 sites
- TRIALNARECRUITING
Allogeneic γδT Cells in Glioblastoma
Allogeneic γδ T (ABOUT) cells — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
EBNK-001 + IL-15 + Pembrolizumab — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma
Survivin-targeted DC Cell Injection
- TRIALEARLY_PHASE1RECRUITING
18F-Fluciclovine PET-MRI in High-grade Glioma
18F-Fluciclovine PET-MRI — 1 site
- TRIALNARECRUITING
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
PET-MRI Brain Scan · Blood draw · Memory testing — 1 site
- TRIALNARECRUITING
Preoperative Preradiotherapy TTFields
TTFields — 1 site
- TRIALNARECRUITING
Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
Combined ultrasound and fluorescence-guided brain tumor resection · Fluorescence-guided brain tumor resection — 1 site
- TRIALEARLY_PHASE1RECRUITING
Imaging Acetadote Metabolism in Glioblastoma
Acetadote — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
LAM561 — 3 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Oral Gallium Maltolate for Recurrent Glioblastoma
Gallium Maltolate · Surgical Intervention — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
pH Measurement of in vivo tissue — 1 site
- TRIALEARLY_PHASE1ENROLLING_BY_INVITATION
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
mRNA vaccine: GV-907、GV-108 — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor
Gallium maltolate
- TRIALPHASE1RECRUITING
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
15.GPC3-CAR T cells — 1 site
- TRIALPHASE1RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Dual-target CAR-NK cells · Cyclophosphamide · Intracranial catheter/reservoir for locoregional delivery — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Narrow by phase or treatment type
By state in the United States
By country
Each country page filters the live registry to listed sites in that country and links to the relevant official national or regional registry for additional local discovery.
Common questions
- How does Trial0 find Glioblastoma options?
- Every list on this page is a live query of ClinicalTrials.gov (API v2) for open interventional trials and expanded-access programs, refreshed at most hourly. Nothing is hand-curated or cached beyond that window.
- Does a match mean the patient is eligible?
- No. Structured registry fields (age, sex, status, phase) give firm matched/not-matched states; free-text criteria can only be checked for mentions, which are signposts to verify with the site. Only the trial site can determine actual eligibility.
- What does the verified site data mean?
- Registry recruiting status is often stale. Trial0 separately records first-hand observations — whether a specific site is really recruiting and whether the investigator accepts outside referrals — each stamped with the date it was verified.
- What does access help cost?
- The eligibility map and new-trial alerts are free. Pro is $49/month or £49/month and covers contact research, draft preparation and approval-first outreach. Trial0 never takes a commission from a provider.
How to use this Glioblastoma trial page
This page is refreshed from live registry data and shows currently open interventional studies and expanded-access programmes. Trial records are leads, not a clinical recommendation.
Use the full matcher to add age, treatment history, biomarkers and a location. It labels published criteria honestly: a mention in free text is a prompt to verify, not a finding of eligibility.
Free alerts help you notice new registry entries. Pro can research a contact and prepare outreach, but Trial0 asks for approval before contacting each trial.
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Data refreshed at most every 1 hour(s).